Literature DB >> 29695614

The Drug-Drug Interaction Potential of Antiviral Agents for the Treatment of Chronic Hepatitis C Infection.

Kimberly L Garrison1, Polina German2, Erik Mogalian2, Anita Mathias2.   

Abstract

Several safe and highly effective direct-acting antiviral (DAA) drugs for chronic hepatitis C virus (HCV) have been developed and greatly increase the number of therapeutic options available to successfully treat HCV infection. However, because treatment regimens contain at least two drugs (e.g., elbasvir and grazoprevir, glecaprevir and pibrentasvir, or sofosbuvir with daclatasvir, simeprevir, ledipasvir, or velpatasvir) and up to five drugs (ombitasvir/paritaprevir/ritonavir plus dasabuvir with or without ribavirin), the potential for drug-drug interactions (DDIs) becomes an important consideration for HCV-infected individuals with comorbidities that require concomitant medications, such as human immunodeficiency virus/HCV coinfection or immunosuppression after liver transplantation. This review details the pharmacokinetics and DDI potential of approved DAAs for the treatment of HCV infection.
Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29695614     DOI： 10.1124/dmd.117.079038

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN： 0090-9556            Impact factor:   3.922


  23 in total

Review 1.  A changing paradigm: management and treatment of the HCV/HIV-co-infected patient.

Authors:  Ameer Abutaleb; Kenneth E Sherman
Journal:  Hepatol Int       Date:  2018-09-20       Impact factor: 6.047

2.  Anti-HIV and Anti-Hepatitis C Virus Drugs Inhibit P-Glycoprotein Efflux Activity in Caco-2 Cells and Precision-Cut Rat and Human Intestinal Slices.

Authors:  Ondrej Martinec; Martin Huliciak; Frantisek Staud; Filip Cecka; Ivan Vokral; Lukas Cerveny
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

Review 3.  Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice.

Authors:  Alberto Corsini; Nicola Ferri; Marco Proietti; Giuseppe Boriani
Journal:  Drugs       Date:  2020-07       Impact factor: 9.546

Review 4.  Usage of HCV viremic organs in liver transplantation to anti-HCV negative recipients: The current status and review of literature.

Authors:  Aslı Çiftçibaşı Örmeci; Çağla Yıldız; Behnam Saberi; Merve Gürakar; Cem Şimşek; Ahmet Gürakar
Journal:  Turk J Gastroenterol       Date:  2019-09       Impact factor: 1.852

Review 5.  Management of Virologic Failure and HIV Drug Resistance.

Authors:  Suzanne M McCluskey; Mark J Siedner; Vincent C Marconi
Journal:  Infect Dis Clin North Am       Date:  2019-06-27       Impact factor: 5.982

6.  In Vitro Assessment of Transporter Mediated Perpetrator DDIs for Several Hepatitis C Virus Direct-Acting Antiviral Drugs and Prediction of DDIs with Statins Using Static Models.

Authors:  Xiaoyan Chu; Grace Hoyee Chan; Robert Houle; Meihong Lin; Jocelyn Yabut; Christine Fandozzi
Journal:  AAPS J       Date:  2022-03-21       Impact factor: 4.009

7.  Drug-Drug Interactions in Italian Patients with Chronic Hepatitis C Treated with Pangenotypic Direct Acting Agents: Insights from a Real-World Study.

Authors:  Alessandra Mangia; Francesco Scaglione; Pierluigi Toniutto; Mario Pirisi; Nicola Coppola; Giovanni Di Perri; Gema Alvarez Nieto; Stefano Calabrese; Candido Hernandez; Valentina Perrone; Luca Degli Esposti; Stefano Fagiuoli
Journal:  Int J Environ Res Public Health       Date:  2021-07-03       Impact factor: 3.390

8.  Direct-acting antiviral treatments display excellent outcomes even in older HCV-infected patients at increased risk of fibrosis.

Authors:  Huan Xia; Yaping Zhang; Silvere D Zaongo; Jing Liang; Xiaowen Gong; Yue Hu; Ping Ma; Fengmei Wang
Journal:  Ann Transl Med       Date:  2021-05

Review 9.  Current treatment for hepatitis C virus/human immunodeficiency virus coinfection in adults.

Authors:  Ratchapong Laiwatthanapaisan; Apichet Sirinawasatien
Journal:  World J Clin Cases       Date:  2021-06-26       Impact factor: 1.337

Review 10.  Management and Treatment of Hepatitis C: Are There Still Unsolved Problems and Unique Populations?

Authors:  Virginia Solitano; Maria Corina Plaz Torres; Nicola Pugliese; Alessio Aghemo
Journal:  Viruses       Date:  2021-06-01       Impact factor: 5.048
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.